Christopher R Behrens is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cancer therapeutics, holding a total of 4 patents. His work focuses on innovative approaches to target cancer cells, particularly through the use of antibodies.

Latest Patents

Among his latest patents are groundbreaking inventions such as "Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics." This patent describes human anti-CD46 antibodies that can internalize and enter tumor cells via the macropinocytosis pathway. Additionally, it includes antibody-drug conjugates (ADCs) developed from these antibodies for the diagnostic and therapeutic targeting of CD46-overexpressing tumors. Another notable patent is "Anti-CD46 antibodies and methods of use," which discloses methods for treating subjects with cancer characterized by a modification at biomarker 1q21. This involves administering a therapeutically effective amount of an anti-CD46 antibody to the subject.

Career Highlights

Christopher R Behrens is affiliated with the University of California, where he continues to advance research in cancer treatment. His innovative work has positioned him as a key figure in the development of targeted therapies.

Collaborations

He collaborates with esteemed colleagues such as Yang Su and Bin Liu, contributing to a dynamic research environment focused on cancer therapeutics.

Conclusion

Christopher R Behrens is a leading inventor whose work in cancer therapeutics is paving the way for new treatment options. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.